← Back to Search

Molecular Nanotechnology for Non-Hodgkin's Lymphoma

N/A

Recruiting

Led By Narendranath Epperla, MD

Research Sponsored by Ohio State University Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically confirmed treatment naive DLBCL. Subtypes including high grade B-cell lymphoma, not otherwise specified (NOS) and de-novo DLBCL including germinal center B-cell type (GCB) and non-GCB subtypes.

Receiving treatment with curative intent.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

Study Summary

This trial is testing how well a nanochip can detect genetic markers for diffuse large B-cell lymphoma to help predict how well a person will respond to treatment.

Who is the study for?

This trial is for people with a specific blood cancer called diffuse large B-cell lymphoma (DLBCL) who haven't been treated before. Participants must plan to get all their care at Ohio State University, aim for a cure with treatment, and go through 6 cycles of chemotherapy. They also need to be able to give consent.Check my eligibility

What is being tested?

The study is testing nanochip technology (ILN biochip) to see how well it can monitor the effectiveness of treatments in real-time and detect any return of the disease in patients with DLBCL. Researchers are looking for genetic markers that could predict treatment outcomes.See study design

What are the potential side effects?

Since this trial focuses on monitoring technology rather than direct treatment, there may not be side effects related directly to the ILN biochip itself. However, standard chemotherapy side effects apply.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a specific type of untreated lymphoma.

Select...

I am undergoing treatment aimed at curing my condition.

Select...

I am scheduled for 6 chemotherapy sessions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Early detection of relapse

Treatment response

Trial Design

1Treatment groups

Experimental Treatment

Group I: Diagnostic (ILN biochip testing)Experimental Treatment1 Intervention

Participants' blood samples undergo ILN biochip testing at diagnosis, before and after every course of chemotherapy, every 3 months for 2 years, and at relapse.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor

320 Previous Clinical Trials

290,067 Total Patients Enrolled

Narendranath Epperla, MDPrincipal Investigator - Ohio State University Comprehensive Cancer Center

Ohio State University Comprehensive Cancer Center

1 Previous Clinical Trials

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies left for participation in this research?

"According to clinicialtrials.gov, this clinical trial is actively looking for participants. It was first made available on September 26th 2018 and has since been edited as recently as June 2nd 2022."

Answered by AI

How many participants have been accepted into this trial thus far?

"Correct. The details listed on clinicaltrials.gov signify that this study is currently enrolling participants. It was initially published on September 26th 2018, and the most recent update occurred June 2nd 2022. 40 patients are needed to be enrolled from a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma

Narendranath Epperla 2018. "Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03656835.